Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Cash from Investing Activities of $6.1 million for Q2 2026, down 50.54% year-over-year from $12.4 million in Q2 2025, and up 173.97% quarter-over-quarter from -$8.3 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Cash from Investing Activities for 16 consecutive years, with $6.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 50.54% year-over-year to $6.1 million; the TTM figure through Jun 2026 stood at -$17.8 million (up 67.58% YoY), while the FY2025 annual figure was $8.8 million, up 119.2% from the prior year.
- Cash from Investing Activities grew to $6.1 million in Q2 2026 per AMRN's latest filing, from -$8.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $99.0 million in Q1 2022 and bottomed at -$71.0 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged $6.1 million across 5 years, with a median of $5.4 million in 2024.
- On a YoY basis, Cash from Investing Activities climbed as much as 246.45% in 2024 and fell as far as 283.8% in 2024.
- Amarin Corp Plc\Uk's Cash from Investing Activities stood at -$27.8 million in 2022, then plunged by 155.22% to -$71.0 million in 2023, then surged by 67.83% to -$22.8 million in 2024, then jumped by 84.61% to -$3.5 million in 2025, then jumped by 274.57% to $6.1 million in 2026.
- Business Quant data shows AMRN's Cash from Investing Activities at $6.1 million in Q2 2026, -$8.3 million in Q1 2026, and -$3.5 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -2.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -569.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.35 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.11 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 6.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.14 Mn |
| Jun 30, 2026 | 6.14 Mn |
| Mar 31, 2026 | -8.30 Mn |
| Mar 31, 2026 | -8.30 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | -12.13 Mn |
| Sep 30, 2025 | -12.13 Mn |
| Jun 30, 2025 | 12.41 Mn |
| Jun 30, 2025 | 12.41 Mn |
| Mar 31, 2025 | 12.06 Mn |
| Mar 31, 2025 | 12.06 Mn |
| Dec 31, 2024 | -22.84 Mn |
| Dec 31, 2024 | -22.84 Mn |
| Sep 30, 2024 | -56.55 Mn |
| Sep 30, 2024 | -56.55 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 28.72 Mn |
| Mar 31, 2024 | 28.72 Mn |